Clinical Trial Update: Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating irinotecan, S-1, and bevacizumab for unresectable or recurrent colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Irinotecan (Camptosar) (Irinotecan)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Taiho Pharmaceutical Co., Ltd. | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED